In this episode of the pharmaphorum podcast, our news editor Richard Staines talks to Richard Francis, who took over as CEO of gene therapy company Purespring Therapeutics earlier this month.

Francis was previously CEO of Sandoz, Novartis’ generics and biosimilars division, where he led the development of biosimilars and also sat on the Swiss pharma company’s executive committee.